

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION WITH JD HEALTH

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on March 20, 2026, the Company entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with JD Health International Inc. (“**JD Health**”).

Pursuant to the Strategic Cooperation Agreement, JD Health will serve as the exclusive online launch platform for a number of the Company’s major new products in the respiratory and rhinology therapeutic areas over the next three years. The principal terms of the cooperation include the following: (i) JD Health will utilize its online platform and supply chain service capabilities to provide online launch sales and patient service support for the Company’s new products; (ii) JD Health will leverage its capabilities in prescription management and patient administration to assist the Company in enhancing the commercialization efficiency of new products; and (iii) both parties will explore cooperative chronic disease management models based on internet healthcare. The cooperation aims to leverage the respective strengths of both parties in innovative drug development and digitalized medical supply chain capabilities, to jointly promote the rapid adoption of high-quality respiratory treatment solutions and to provide patients with more convenient, standardized medication and chronic disease management services.

The Company has maintained a long-term focus on research, development and production in the respiratory and rhinology sector. Backed by a globally competitive technology platform for inhalation formulations, it continues to advance the development and upgrading of innovative drugs, and has established a product pipeline covering disease areas including allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, creating a comprehensive disease management system that features both single-agent and combination formulations to serve patients of all ages across the entire disease continuum. The Company delivers molecular drugs, including small molecules and small nucleic acids, via inhalation and draws on their mechanisms of action at the cellular and genetic levels to pursue a better efficacy-safety balance, representing a key step in its shift from complex formulations to original innovative drugs. This approach broadens the therapeutic scope to serious diseases with unmet clinical needs worldwide, including those affecting the respiratory and central nervous systems, while refining immunomodulatory effects through local delivery strategies to form an integrated innovation pathway of “local inhalation delivery + targeted cellular delivery + gene/protein regulation”.

Given the sizeable patient population and the long-term management characteristics of such diseases in China, the Board considers that the entering into of the Strategic Cooperation Agreement is in the interests of the Company and its shareholders as a whole. The cooperation is expected to enhance patient accessibility to the Company's products and improve the commercialization efficiency of new products.

The Strategic Cooperation Agreement does not constitute a notifiable transaction of the Company.

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms, the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

CF PharmTech, Inc.

長風藥業股份有限公司

Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, March 23, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.